

**ADHERIUM INVESTOR CONFERENCE CALL**

**Melbourne, Australia, 24 August 2017** -- Adherium Limited (ASX: ADR) will host a conference call on Tuesday, August 29, 2017 at 11:00 am AEST to discuss its financial results for the year ended June 30, 2017 and provide an update on current strategic initiatives.

Arik Anderson, Chief Executive Officer will host the call and will be joined by Adherium's Founder and Executive Director, Garth Sutherland and Rob Turnbull, Chief Financial Officer.

**Conference Call details:**

**Conference ID:** 7552 7150

**Dial-in Details:**

Australia: 1800 123 296 or +61 2 8038 5221

New Zealand: 0800 452 782

Hong Kong: 800 908 865

United States: 1855 293 1544

**Webcast:** <http://www.openbriefing.com/OB/2640.aspx>

For overseas participants, the conference call will commence at:

- 1:00pm on Tuesday, August 29, 2017 (**New Zealand Standard Time**)
- 9:00am on Tuesday, August 29, 2017 (**Hong Kong Time**)
- 9:00pm on Monday, August 28, 2017 (**U.S. Eastern Time**)

A recording of the call will be made available in the 'Investor Centre' section of the Company website at <http://adherium.com/investors/> and also at <http://www.openbriefing.com/>

[www.adherium.com](http://www.adherium.com)   [www.smartinaler.com](http://www.smartinaler.com)

**Contact:****Australia and New Zealand**

Rudi Michelson

Monsoon Communications

D: +61 3 9620 3333

E: [rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

**North America**

Matt Ventimiglia

Lazar Partners

D: + 212-599 1265

E: [mventimiglia@lazarpartners.com](mailto:mventimiglia@lazarpartners.com)

**Europe**

Sue Charles/Tim Watson

Instinctif Partners

D: +44 20 7457 2020

E: [adherium@instinctif.com](mailto:adherium@instinctif.com)



## Announcement

### **Adherium's Smartinhaler™**

Adherium's innovative Smartinhaler™ product platform integrates a Bluetooth enabled sensor, smartphone application and cloud services to detect, record and monitor actual usage of inhaled medications. The Smartinhaler platform provides patients and physicians with critical data that can increase adherence to inhaled medication regimens, resulting in improved management of chronic respiratory conditions. Used in more than 65 projects and referenced in 56 peer reviewed journal articles, the Smartinhaler platform's clinical outcomes data have proven that it can improve adherence by up to 59% in adults and 180% in children. These improvements were associated with a 60% reduction in severe respiratory episodes in adults, leading to improved quality-of-life and demonstrating a substantial gain over current best practice treatment. The Smartinhaler device has received FDA 510(k) notifications for clearance to market and has CE Marks for its devices and software.

### **About Adherium**

Adherium is a provider of digital health solutions. The Company develops, manufactures and supplies patients, pharmaceutical companies, healthcare providers and contract research organizations with the broadest range of "smart" medication sensors for respiratory medications to address sub-optimal medication use and improve health outcomes in chronic disease.

Adherium operates globally from bases in the USA, Europe and Australasia.